{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T08:02:04Z","timestamp":1795075324243,"version":"4.10.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"9757","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/s0140-6736(10)62002-8","type":"journal-article","created":{"date-parts":[[2010,12,4]],"date-time":"2010-12-04T04:32:30Z","timestamp":1291437150000},"page":"2009-2017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":305,"title":["Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial"],"prefix":"10.1016","volume":"376","author":[{"given":"Catriona","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Leighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ancliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Masurekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Goulden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"R\u00e9v\u00e9sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Darbyshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaskar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(10)62002-8_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/leu.2009.276","article-title":"Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985\u20132000)","volume":"24","author":"Schrappe","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(10)62002-8_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11912-008-0070-3","article-title":"Relapsed acute lymphoblastic leukemia: current status and future opportunities","volume":"10","author":"Harned","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/S0140-6736(10)62002-8_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2141.2000.01891.x","article-title":"The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study","volume":"108","author":"Lawson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2005.05572.x","article-title":"Outcome after first relapse in childhood acute lymphoblastic leukaemia\u2014lessons from the United Kingdom R2 trial","volume":"130","author":"Roy","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib5","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib6","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1200\/JCO.2007.10.7508","article-title":"Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952","volume":"25","author":"Malempati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2009.264","article-title":"Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985\u20132001","volume":"24","author":"Krishnan","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(10)62002-8_bib8","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib9","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2002-05-1600","article-title":"Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia","volume":"101","author":"Stam","year":"2003","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62002-8_bib10","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2007-07-102525","article-title":"High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia","volume":"111","author":"von Stackelberg","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62002-8_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1200\/JCO.1985.3.7.998","article-title":"Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia","volume":"3","author":"Wells","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.2002.03706.x","article-title":"A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood \u2018high-risk\u2019 acute lymphoblastic leukaemia: a study of the AIEOP group","volume":"118","author":"Testi","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib13","first-page":"6525","article-title":"Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report","volume":"50","author":"Reid","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(10)62002-8_bib14","first-page":"219","article-title":"In vitro chemosensitivity of lymphoblasts at relapse in childhood leukemia using the MTT assay","volume":"54","author":"Hongo","year":"1991","journal-title":"Int J Hematol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2249.2005.02653.x","article-title":"Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients","volume":"139","author":"Chan","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-003-0701-1","article-title":"Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity","volume":"53","author":"Errington","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(10)62002-8_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib20","series-title":"Generalised Linear Models","author":"McCullagh","year":"1983"},{"key":"10.1016\/S0140-6736(10)62002-8_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/S0140-6736(10)62002-8_bib22","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/S0140-6736(10)62002-8_bib23","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group","volume":"78","author":"Henze","year":"1991","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62002-8_bib24","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib25","first-page":"664","article-title":"A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University \u201cLa Sapienza\u201d of Rome","volume":"82","author":"Testi","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/S0140-6736(10)62002-8_bib26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib27","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(10)62002-8_bib28","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(10)62002-8_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","article-title":"Surrogate endpoints and FDA's accelerated approval process","volume":"24","author":"Fleming","year":"2005","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/S0140-6736(10)62002-8_bib30","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/jnci\/96.20.1495","article-title":"Accelerated approval seen as triumph and roadblock for cancer drugs","volume":"96","author":"Susman","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(10)62002-8_bib31","doi-asserted-by":"crossref","first-page":"18814","DOI":"10.1074\/jbc.M400931200","article-title":"A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences","volume":"279","author":"Parker","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/S0140-6736(10)62002-8_bib32","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1111\/j.1582-4934.2009.00888.x","article-title":"Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response","volume":"13","author":"Karl","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/S0140-6736(10)62002-8_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/cmi.2009.59","article-title":"Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response","volume":"6","author":"Cao","year":"2009","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/S0140-6736(10)62002-8_bib34","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/sj.leu.2403924","article-title":"Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials","volume":"19","author":"Gibson","year":"2005","journal-title":"Leukemia"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673610620028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673610620028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T23:59:54Z","timestamp":1758844794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673610620028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":33,"journal-issue":{"issue":"9757","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0140673610620028"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(10)62002-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.7823960.8163058","asserted-by":"object"}]},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(10)62002-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(10)62194-0","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}